Pemphigus is a group of rare autoimmune skin diseases that require lifelong medical care. Understanding treatment options—from well-established medications to innovative therapies being studied in clinical trials—can help patients and their families navigate this challenging condition with greater confidence and hope.

How Doctors Approach Pemphigus Treatment Today

Treating pemphigus means managing a long-term condition rather than curing it completely. The main goal is to control the disease so that painful blisters and sores heal, prevent new ones from appearing, and help patients return to a quality of life that feels as normal as possible. Because pemphigus affects each person differently, treatment plans are highly individual and depend on the type of pemphigus, how severe the symptoms are, which parts of the body are affected, and the patient’s overall health.^[1]

Treatment usually follows three phases. The first is called the control phase, where doctors use strong medications to quickly suppress disease activity until no new blisters form. The second is the consolidation phase, during which medications are maintained at the same dose until all existing lesions have completely healed. Finally, the maintenance phase involves gradually tapering medications to find the lowest effective dose that prevents new blisters from appearing.^[13]

Standard treatments approved by medical societies exist, and there is also ongoing research into new therapies through clinical trials. These research studies test promising drugs that may offer better outcomes or fewer side effects than current options. Some patients participate in trials when standard treatments don’t work well or cause too many problems.^[12]

One important thing to understand is that pemphigus is not contagious—you cannot catch it from someone else or spread it to others. It happens when the body’s immune system mistakenly attacks healthy skin cells, causing the layers of skin to separate and form blisters. Treatment focuses on calming down this immune response while helping the skin heal and preventing infections, which are a serious risk with open sores.^[1]

Standard Treatment Approaches

Corticosteroids: The Foundation of Pemphigus Treatment

Corticosteroids (also called steroids) remain the most important and widely used treatment for pemphigus. These medications work by suppressing the immune system and reducing inflammation throughout the body. For most patients, corticosteroids are the first line of treatment because they can quickly bring the disease under control.^[2]

The most commonly prescribed oral steroid is prednisone, which patients take as pills. Doctors usually start with higher doses—sometimes 1 milligram per kilogram of body weight per day—to rapidly stop new blisters from forming. This intensive treatment typically continues until the skin begins healing, which usually takes several weeks. Some patients may also receive prednisolone, which is similar to prednisone and works in the same way.^[7][15]

For patients with milder disease affecting only small areas, doctors may recommend topical corticosteroid creams, injections directly into the lesions, or steroid mouthwashes for oral sores. These localized treatments can be effective when only the mouth or a limited area of skin is involved.^[13]

While corticosteroids are highly effective, they come with significant side effects, especially when used at high doses or for extended periods. Common problems include weight gain, increased appetite, mood changes, difficulty sleeping, high blood pressure, increased blood sugar that can lead to diabetes, thinning of the bones (osteoporosis), easy bruising and thinning of the skin, increased risk of infections, stomach ulcers, and changes in how body fat is distributed that can cause a rounded face sometimes called “moon face.” Because of these risks, doctors work carefully to reduce steroid doses as soon as the disease is under control.^[7][10]

Immunosuppressive Medications

Because long-term steroid use causes so many problems, doctors typically add another type of medication called an immunosuppressant once the initial disease is under control. These drugs also suppress the immune system but work through different mechanisms than steroids. By combining treatments, doctors can gradually lower steroid doses while still keeping the disease controlled. This approach is called “steroid-sparing” therapy.^[12]

Azathioprine (brand names Imuran and Azasan) is one of the most commonly used immunosuppressants for pemphigus. It works by interfering with the production of certain immune cells. Doctors usually start azathioprine after the initial treatment phase, and patients may continue taking it for months or years. Some healthcare providers check a blood test for an enzyme called thiopurine methyltransferase (TPMT) before starting azathioprine, because people with low levels of this enzyme may experience more side effects.^[13][15]

Mycophenolate mofetil (brand names CellCept and Myfortic) is another frequently prescribed immunosuppressant. It works by blocking the multiplication of lymphocytes, which are immune cells involved in the autoimmune attack. Some studies suggest mycophenolate may help patients improve faster in the short term, though its long-term steroid-sparing benefits are similar to other immunosuppressants.^[13][15]

Other immunosuppressants that may be used include cyclophosphamide (Cytoxan), which is usually reserved for severe cases that don’t respond to other treatments because of its potential for serious side effects, and cyclosporine (Gengraf, Neoral, Sandimmune), which can be effective but requires careful monitoring.^[13]

All immunosuppressive medications increase the risk of infections because they weaken the body’s ability to fight bacteria, viruses, and other germs. Patients taking these drugs need to be vigilant about avoiding sick people, practicing good hygiene, and contacting their doctor promptly if they develop fever or signs of infection.^[23]

Duration and Adjustment of Treatment

The duration of treatment varies greatly among patients. It typically takes about three weeks for new blisters to stop forming after starting treatment, and existing blisters may take around eight weeks to heal completely. Once the disease is well controlled, doctors begin gradually reducing medication doses.^[23]

The European Dermatology Forum recommends tapering prednisone by 25% every two weeks during the consolidation phase. When the dose reaches below 20 milligrams per day, reductions become smaller—about 5 milligrams every four weeks. This slow tapering helps prevent disease flare-ups while minimizing side effects.^[12]

Many patients require treatment for several years. Some fortunate individuals eventually achieve complete remission and can stop all medications, but others need ongoing maintenance therapy to prevent the disease from coming back. If blisters return during the tapering process, doctors may increase medications back to the previous dose or add an additional immunosuppressant.^[2][17]

Supportive Care and Infection Prevention

Beyond immune-suppressing medications, supportive treatments play an important role. Antibiotics may be prescribed if skin infections develop, or sometimes preventively to reduce infection risk. Antifungal medications may be needed because immunosuppressed patients are more prone to fungal infections. For patients with severe oral lesions who struggle to eat, intravenous nutrition might be necessary temporarily.^[15]

Painkilling medications, including topical anesthetic mouthwashes or lozenges, can help control pain from oral ulcers. Some patients find relief using special mouthwashes that combine steroids, lidocaine (for numbing), and antacids to help the mixture coat the mouth—sometimes called “magic mouthwash.”^[15][25]

Treatment in Clinical Trials

Rituximab: A Breakthrough Biologic Therapy

One of the most significant advances in pemphigus treatment has been the use of rituximab (brand name Rituxan), a type of medication called a biologic. Unlike traditional immunosuppressants that broadly suppress the immune system, rituximab specifically targets B-cells—the immune cells that produce the antibodies responsible for attacking skin in pemphigus.^[13]

In June 2018, the U.S. Food and Drug Administration (FDA) approved rituximab specifically for treating adults with moderate to severe pemphigus vulgaris, making it the first biologic approved for this condition. This approval was based on clinical trial results showing rituximab’s effectiveness in helping patients achieve remission.^[13]

Rituximab is given as an intravenous infusion—medication dripped directly into a vein over several hours. The FDA-approved protocol involves two infusions of 1,000 milligrams each, given two weeks apart. This regimen was adapted from protocols used for rheumatoid arthritis. However, researchers have explored whether lower doses might work just as well. Some studies have tested 500-milligram doses (called “low-dose”) and even 100-milligram doses (called “ultralow-dose”), with results suggesting these smaller amounts may provide comparable effectiveness at much lower cost.^[15]

Clinical trials and real-world use have shown that rituximab can be extremely effective, particularly for patients whose disease hasn’t responded well to standard treatments. In one systematic review of pemphigus foliaceus patients treated with rituximab, 63.2% achieved complete remission. However, about 39.5% of patients experienced a relapse at some point, requiring additional treatment. The infection rate was 19.7%, which is significant but reflects the fact that patients were already on other immunosuppressive medications.^[18]

Increasingly, rituximab is being used as a first-line therapy—meaning it’s given early in treatment rather than waiting until other medications fail. Studies suggest that outcomes may be better when rituximab is used earlier in the disease course. Many treatment centers now follow a therapeutic approach where rituximab combined with prednisone is given initially, with other immunosuppressants added only if needed.^[15][18]

Rituximab is usually given in combination with corticosteroids rather than alone. The medication works by depleting B-cells from the bloodstream, and this effect can last for several months. Patients typically need repeated infusions when B-cells return and symptoms begin to recur.^[15]

Intravenous Immunoglobulin (IVIg)

Intravenous immunoglobulin, or IVIg, is another treatment option that has been studied in clinical trials for pemphigus. This therapy involves infusing antibodies collected from thousands of blood donors into the patient’s bloodstream. These antibodies can help modulate the immune system’s abnormal response.^[18]

In studies of pemphigus foliaceus patients treated with IVIg, 62.5% achieved complete remission with no relapses or infections reported. The average follow-up period was about 25 months. IVIg appears to be particularly useful for patients who cannot tolerate other immunosuppressive medications or when other treatments have failed.^[18]

Some patients receive combination treatment with both rituximab and IVIg. Research suggests that outcomes may be better when rituximab is given first, followed by IVIg, rather than the reverse order. The combination appears to provide more sustained disease control in some difficult cases.^[18]

Emerging Therapies and Research Directions

Researchers continue exploring new treatment approaches for pemphigus through clinical trials. These studies test innovative molecules and therapies that may offer advantages over current options. Clinical trials typically proceed through three phases: Phase I focuses on safety and determining appropriate doses in small numbers of patients; Phase II examines whether the treatment is effective and continues safety monitoring in larger groups; and Phase III compares the new treatment directly with standard therapy in even larger patient populations.^[12]

Some areas of active research include testing other biologic medications that target different parts of the immune system, exploring combinations of existing drugs in new ways, and investigating medications already approved for other autoimmune diseases to see if they help pemphigus patients. Researchers are also studying biomarkers—measurable indicators in the blood—that might help predict which patients will respond best to which treatments.^[12]

Clinical trials for pemphigus are conducted at medical centers around the world, including in the United States, Europe, and other regions. Patients interested in participating typically need to meet specific eligibility criteria related to disease type, severity, previous treatments, and overall health. Healthcare providers can help patients find appropriate trials and determine if participation might be beneficial.^[12]

Most common treatment methods

• Corticosteroids
  • Oral prednisone or prednisolone tablets to suppress immune system and reduce inflammation throughout the body
  • Topical corticosteroid creams applied directly to affected skin areas for localized disease
  • Corticosteroid injections directly into lesions for small, limited areas of involvement
  • Steroid mouthwashes, pastes, or aerosols for treating painful mouth sores and ulcers
  • High initial doses gradually tapered to lowest effective maintenance level
• Immunosuppressants
  • Azathioprine (Imuran, Azasan) to reduce immune cell production and spare steroid use
  • Mycophenolate mofetil (CellCept, Myfortic) to block lymphocyte multiplication
  • Cyclophosphamide (Cytoxan) reserved for severe, treatment-resistant cases
  • Cyclosporine (Gengraf, Neoral, Sandimmune) as alternative immunosuppressive option
  • Used in combination with corticosteroids to allow lower steroid doses
• Biologic therapy
  • Rituximab (Rituxan) targets B-cells that produce disease-causing antibodies
  • FDA-approved for moderate to severe pemphigus vulgaris in adults
  • Given as intravenous infusions, typically two doses of 1,000 mg two weeks apart
  • Can be used as first-line therapy or for treatment-resistant disease
  • Usually combined with corticosteroids for optimal results
• Intravenous immunoglobulin (IVIg)
  • Infusion of pooled antibodies from blood donors to modulate immune response
  • Useful for patients who cannot tolerate standard immunosuppressants
  • Sometimes combined with rituximab for enhanced disease control
  • Associated with lower infection risk compared to some other treatments
• Supportive care
  • Antibiotics for treating or preventing bacterial skin infections
  • Antifungal medications for patients at high risk of fungal infections
  • Topical anesthetic mouthwashes and lozenges for oral pain relief
  • “Magic mouthwash” combining dexamethasone, lidocaine, and antacid for mouth sores
  • Pain medications for severe discomfort from extensive blistering
  • Intravenous nutrition when oral lesions prevent adequate eating